Investor Presentation

August 11, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, Fort, G Block, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai 400 051 Scrip Code: 506414 Trading Symbol: FERMENTA Dear Sir, Sub.: Intimation of Earnings Presentation – Q1/FY27 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Earnings Presentation for Q1/FY27 for your information. The said Earnings Presentation will thereafter be uploaded on Company’s website at www.fermentabiotech.com This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kindly take the same on records. Thanking you, Yours faithfully, for FERMENTA BIOTECH LIMITED Varadvinayak Khambete Company Secretary and Head - Legal Membership No. A33861 Encl: As above Fermenta Biotech Ltd Q1FY27 presentation 11August 2026 Disclaimer Byviewingthispresentation,therecipientagreesthatneitherFermentaBiotechLimited(“FBL”)noranyofits affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on the information contained herein. The recipient furtheragreestoindemnifyandholdharmlessFBLanditsrepresentativesfromanyclaims,losses,ordamages arisingoutoforrelatedtoanyunauthorizeduseordistributionofthismaterialoranybreachoftheseterms. This presentation may contain forward-looking statements relating to FBL)s future business, financial performance,industrytrends,strategy,orobjectives.Thesestatementsarebasedoncurrentassumptionsand expectations and involve known and unknown risks and uncertainties that may cause actual results to differ materially. Factors such as economic conditions, regulatory changes, market dynamics, technological developments,andglobaleventscouldimpactfutureoutcomes. Forward-looking statements are identified by terms such as “expects” “intends” “may” “believes” “plans” “will” and similar expressions. FBL undertakes no obligation to revise or update these statements. This presentationdoesnotconstituteanofferorinvitationtobuyorsellsecuritiesandshould notberelieduponfor anyinvestmentdecisions. Investor presentation Q1FY27 | 2 As preventive healthcare awareness rises, global demand is accelerating for science-backed, top-quality nutritional ingredients. Fermenta pairs process and molecular expertise with science-validated capability to deliver best-in-class ingredients, trusted by leading brands across the pharmaceutical, dietary supplement, food and beverage, veterinary, and animal nutrition industries. Our edge: decades of global-scale, complex manufacturing and research- driven custom solutions in green chemistry, APIs and intermediates, and environmental solutions. Chemistry built to solve, engineered to scale, and proven in the field by 400+ discerning customers across 60+ countries. Investor presentation Q1FY27 | 3 Q1FY27 Highlights Financials (consolidated) with and without Real Performance Estate Q1FY27 ex-real Q1FY27 Revenue near flat sequentially at INR 126.2 crore, flat estate QoQ, with human nutrition revenue up 24% QoQ to INR 76.5 crore and segment volumes up 18% QoQ across INR 124.3 crore INR 126.2 crore Fermenta'slargest business. Revenue (down 12% YoY, flat (down 13% YoY, flat QoQ) QoQ) India strengthened as a market, rising to 47% of consolidated revenue in April–June 2026 from 35% a INR 22.3 crore INR 22.4 crore EBITDA (down 37% YoY, down year earlier, as domestic demand deepened across (down 39% YoY, down 11% QoQ) 10% QoQ) nutrition and APIs. Growth broadens beyond Vitamin D3: Other APIs and INR 9.5 crore — Profit after tax Intermediates up 18% YoY to INR 11.6 crore, Green (down 56% YoY, down 49% QoQ) Chemistry Solutions / Enzymes up 15% YoY to INR 2.3 crore, and Others within nutrition up 28% YoY to INR 11 EPS (diluted) INR3.34 — crore. Animal nutrition remains the soft spot: volumes down 52% QoQ and 20% YoY with average realisation down 40% YoY; the Company chose volume discipline over The YoY comparison is against an exceptionally strong chasing a weak price. April–June 2025 base, which carried INR 2.7 crore of non-recurring insurance income and INR 1.6 crore of Two post-quarter milestones: FSSAI approval for real-estate value unlocking; neither recurs in the VITADEE Green® (6 July 2026) for health supplements, current quarter. Sequential human nutrition growth and nutraceuticals and food products; and a 7th-place ranking nationwide in India’s Great Mid-size stronger India reaffirm Fermenta's structural direction. Workplaces 2026. Investor presentation Q1FY27 | 4 Lines of Business Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 -Human Vitamin D3 -Animal Others Premium supplements, food Specialized formulations for Customized Food Premixes, fortification, and pharmaceuticals livestock and poultry feed Fortified Rice Kernels (FRK) and for nutraceutical companies, food applications targeting animal feed Specialized Nutraceutical processors, and pharmaceutical manufacturers, poultry farms, and Ingredients firms dairy producers Others Diversified biotechnology and chemical solutions for industrial and environmental applications API & Intermediates Green Chemistry Environmental Pharmaceutical ingredients and Enzymatic technologies for Biotechnolgy-based remediation custom synthesis for generic drug eco-friendly processes serving solutions for for water treatment manufacturers and chemical manufacturers, biofuel and waste management sectors pharmaceutical developers producers, and cosmetic companies Investor presentation Q1FY27 | 5 Revenue Mix (Consolidated) Geographical Revenue Mix Q1FY27 Q4FY26 QoQ Q1FY26 YoY (consolidated) excluding real estate value (INR crore) (INR crore) change (%) (INR crore) change (%) unlocking Nutrition Business Vitamin D3 –Human 76.5 61.7 +24% 84.7 -10% 19% +1% 20% Nutrition Vitamin D3 –Animal 12.6 22.9 -45% 21.4 -41% Nutrition 13% -3% 10% Others 11.0 9.5 +16% 8.5 +28% Other Business 23% -10% Other APIs and 33% 11.6 18.1 -36% 9.8 +18% Intermediates Green Chemistry Solutions / 2.3 6.9 -67% 2.0 +15% Enzymes Environmental Solutions 6.0 0.8 +619% 6.6 -8% India +12% Other Income 6.2 6.7 -8% 10.4 -41% 35% Europe North America Value Unlocking Others Real Estate 0 0 -100% 1.6 -100% Q1FY26 % Change Q1FY27 Investor presentation Q1FY27 | 6 Income Statement—Key Numbers (Consolidated) Amount in INR crore Q1FY27 Q1FY26 % Change INCOME Revenue from operations 121.8 136.3 The YoY comparison is against a strong Other income 4.4 8.8 April–June 2025 base: human nutrition volumes rose 18% QoQ, India reached 47% Total Income 126.2 145.0 -13% of revenue, and there are no exceptional EXPENSES items in the quarter Cost of materials consumed* 38.8 27.5 Purchases of stock-in-trade 9.8 15.6 Change in inventories (6.5) 8.8 Employee benefits expense 23.0 20.4 Finance costs 2.5 3.1 Depreciation and amortisation 5.2 5.8 Other expenses 38.7 35.7 Total Expenses 111.5 116.9 PROFITABILITY Profit before tax 14.7 28.1 Tax expense 5.2 6.6 Profit after tax 9.5 21.6 -56% * Net of the INR 2.0 crore non-cash write-back of the earlier inventory write-down Investor presentation Q1FY27 | 7 Cost Breakdown (Without Real Estate) Cost Structure Against the FY26 Base Raw material costs at 35% of revenue in Q1FY27, against 37% in FY26 (38% in FY25), which reflected an (% of Revenue) improved sourcing mix. Cost Component Q1FY27 FY26 FY25 Employee costs at 19% of revenue, against 16% in FY26, when capacity expansion added heads ahead of Raw Materials 35% 37% 38% the Dahej scale-up. Employee Costs 19% 16% 15% Manufacturing expenses at 12% in Q1FY27, against 12% in FY26, which had improved from 15% in FY25 on Manufacturing Expenses 12% 12% 15% operating lev [Showing first 8,000 characters — download PDF for full document]